Table 3.
Medical Conditions Managed with Cannabigerol-Predominant Cannabis and Perceived Efficacy (N=127)
| Medical condition | % endorsed | n | Range | Mean | Standard error |
|---|---|---|---|---|---|
| Anxiety | 51.2 | 62 | 1–5 | 2.02 | 0.11 |
| Chronic pain | 40.9 | 48 | 1–4 | 2.15 | 0.11 |
| Depression | 33.1 | 40 | 1–4 | 2.13 | 0.14 |
| Insomnia/disturbed sleep | 30.7 | 37 | 1–4 | 2.22 | 0.15 |
| Migraine/headache | 18.1 | 22 | 1–4 | 2.23 | 0.20 |
| Other inflammatory problems | 18.1 | 22 | 1–3 | 2.14 | 0.17 |
| Acute pain | 16.5 | 20 | 1–4 | 2.25 | 0.18 |
| Nausea | 14.2 | 17 | 1–3 | 2.06 | 0.20 |
| Irritable bowel syndrome | 13.4 | 17 | 1–3 | 1.88 | 0.21 |
| Cancer treatment | 7.1 | 9 | 1–4 | 2.11 | 0.42 |
| Autoimmune disease | 7.1 | 9 | 1–4 | 2.89 | 0.31 |
| Bacterial infection/antibiotic | 6.3 | 7 | 1–4 | 2.14 | 0.40 |
| High blood pressure | 6.3 | 8 | 1–4 | 2.50 | 0.46 |
| Osteoarthritis | 5.5 | 6 | 2–3 | 2.50 | 0.22 |
| Menstrual cramps | 4.7 | 6 | 1–3 | 2.33 | 0.33 |
| Premenstrual syndrome | 3.9 | 5 | 2–3 | 2.40 | 0.24 |
| Crohn's/ulcerative colitis | 3.1 | 4 | 1–3 | 1.75 | 0.48 |
| Glaucoma | 3.1 | 3 | 1–4 | 2.67 | 0.88 |
| Fibromyalgia | 5.5 | 7 | 1–3 | 2.14 | 0.34 |
| Cancer treatment-related symptoms | 2.4 | 3 | 2–2 | 2.00 | 0.00 |
| Menopausal symptoms | 2.4 | 3 | 2–3 | 2.67 | 0.33 |
| Seizures/epilepsy | 2.4 | 2 | 1–4 | 2.33 | 0.88 |
| Endometriosis | 2.4 | 3 | 1–3 | 1.67 | 0.67 |
| Rheumatoid arthritis | 3.1 | 3 | 2–3 | 2.33 | 0.33 |
| Multiple sclerosis | 0.8 | 1 | 2–2 | 2.00 | 0.00 |
| Premenstrual dysphoric disorder | 0.8 | 1 | 3–3 | 3.00 | 0.00 |
| Huntington's disease | 0.0 | ||||
| Other | 9.4 |
% endorsed refers to the percentage of the total sample (N=127) who reported use for each medical condition. n refers to the total number of participants who provided efficacy ratings. Efficacy scale ranged from 1 (very much improved) to 7 (very much worsens). Conditions are listed in order of the % who endorsed use for the condition.